Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Amyotrophic Lateral Sclerosis, Nervous System Diseases, Sclerosis, Motor Neuron Disease, Spinal Cord Diseases, Central Nervous System Diseases, Neurodegenerative Diseases, Neuromuscular Diseases, ALS
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Atlanta, Georgia + 3 more

Conditions: Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: gemcitabine hydrochloride, floxuridine, proteomic profiling, matrix-assisted laser desorption/ionization time of flight mass spectrometry, liquid chromatography, yttrium Y 90 anti-CEA monoclonal antibody cT84.66, laboratory biomarker analysis, mass spectrometry, pharmacological study; Drug · Genetic · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hereditary Angioedema (HAE)
Interventions: C1 esterase inhibitor [human] liquid, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more

Conditions: Social Intelligence
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Cardiac/ Non-Thoracic Surgery, Abdominal Surgery, Pelvic Surgery, Major Peripheral Vascular Surgery
Interventions: EV1000 Clinical Platform with Assisted Fluid Management (AFM) Feature; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 10
States / cities: Loma Linda, California • Sacramento, California • Boston, Massachusetts + 7 more

Conditions: Asthma
Interventions: ELLIPTA DPI, GSK MDI, AZ MDI; Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more

Conditions: Achalasia
Interventions: POEM Procedure; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Refractory Depression, Anxiety Disorders, Neurodegenerative Diseases
Interventions: Exosomes; Other
Lead sponsor: Neurological Associates of West Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2000
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Cholecystitis, Chronic Cholecystitis
Interventions: TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia, TIVA - Tachycardia, INH - Hypotension, INH - Hypertension, INH - Bradycardia, INH - Tachycardia; Procedure
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Smoking Cessation
Interventions: Novolin R; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 21 Years to 40 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Post-Operative Urinary Retention
Interventions: At-home Foley Catheter Self-Removal with Passive Void Trial, In-Office Foley Catheter Removal and Backfill Void Trial; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Manchester, New Hampshire

Conditions: Posttraumatic Osteoarthritis, Anterior Cruciate Ligament (ACL) Rupture
Interventions: Synovial Fluid withdrawal at the preoperative clinic visit, Platelet-Rich Plasma (PRP) preparation and injection, Synovial fluid withdrawal at the time of surgery, 3mL synovial fluid withdrawn at the preoperative visit; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Respiratory Distress Syndrome (ARDS)
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cognitive Disorders, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Menlo Park, California • San Diego, California • San Francisco, California + 17 more

Conditions: Abscess
Interventions: Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser Illumination (pre-defined dose), Optical Spectroscopy Measurement, Laser Illumination (patient-specific dose), Standard of care abscess drainage; Drug · Device · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Dysphagia
Interventions: VSL#3; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 65 Years to 99 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Urolithiasis
Interventions: sipIT; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Hershey, Pennsylvania

Conditions: Asthma
Interventions: CXA-10, Placebo; Drug
Lead sponsor: Sally E. Wenzel MD; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Vesicoureteral Reflux, Urinary Tract Infections
Interventions: Trimethoprim-Sulfamethoxazole, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Months to 71 Months
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Wilmington, Delaware • Washington D.C., District of Columbia + 16 more

Conditions: Intraarticular Fracture and Post-traumatic Osteoarthritis
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Joint Infection, Septic Arthritis
Interventions: leukocyte esterase test; Other
Lead sponsor: University of Tennessee; Other
Eligibility: 3 Months to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Bowel Preparation
Interventions: PicoPrep, HalfLytely, bisacodyl; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Clearwater, Florida • Hollywood, Florida • Inverness, Florida + 8 more

Conditions: Healthy Volunteers
Interventions: Vedolizumab SC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers

Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety

Assisted Fluid Management IDE Study

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

Peroral Endoscopic Myotomy (POEM) for Esophageal Motility

Focused Ultrasound and Exosomes to Treat Depression, Anxiety, and Dementias

Evaluation of Liquid vs. Tablet Buprenorphine - 6

Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor

Neuro Biomarkers of Smoking Behavior

Self-discontinuation of Urinary Catheters in a Rural Population

Synovial Fluid Withdrawal or PRP Injection For Acute ACL Tears and Cytokines

The Relationship Between Positive End Expiratory Pressure and Cardiac Index in Patients With Acute Respiratory Distress Syndrome (ARDS) Managed on a Fluid Protocol

HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs

Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia

sipIT2: Improving Adherence to Fluid Intake Guidelines for Kidney Stone Prevention

Anti-Inflammatory Lipid Mediators in Asthma

Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

Inflammatory Response Following Intraarticular Fracture

Utilization of Leukocyte Esterase in the Diagnosis of Pediatric Joint Infections

Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants